When the Sponsor's IT Goes Down, the Trial Goes With It: Cyberattack Exposure in Clinical Trial Delivery
核心洞察
A series of cyberattacks on medtech sponsors, including Boston Scientific and Medtronic, has exposed how sponsor-hosted eClinical infrastructure failures can disrupt active clinical trials mid-study.
When sponsor IT systems go down, sites lose simultaneous access to EDC, IRT/RTSM, eISF, and monitoring dashboards, creating a source documentation crisis and a cascade of protocol deviations.
ICH E6(R3) Section 5.5 and FDA guidance place the contingency-planning burden on sponsors, yet most site SOPs lack a pre-authorized decision tree for initiating backup protocols during an outage.
The call sites dread came in August 2026: Boston Scientific had suffered a cyberattack that knocked out global IT systems and halted order shipping, with no timeline for restoration. For commercial teams and hospital procurement departments scrambling over device delivery, the disruption was visible and immediate. For the coordinators running Boston Scientific-sponsored clinical trials, the disruption was quieter and arguably more dangerous: sponsor-hosted eClinical infrastructure going dark mid-study, with no clear answer on when the lights come back on.
Boston Scientific is not alone. Medtronic confirmed unauthorized access to corporate IT systems between April 13 and April 19, 2026. Stryker and Abbott (搜索) have also faced major incidents this year. The medtech sector is burning through these events fast enough that every site director should treat the next one as a matter of when, not whether.
The Dependency Nobody Mapped
The operational exposure is specific. When a sponsor's IT environment goes down, the blast radius extends well beyond internal finance and logistics teams. Sponsor-hosted EDC instances, IRT/RTSM platforms, electronic investigator site files, and central monitoring dashboards can all become inaccessible to site staff simultaneously. A coordinator who logs into the EDC at 7 AM to enter yesterday's visit data and gets a timeout error has no way of knowing whether the problem is her browser, the site's VPN, or a global cyberattack affecting tens of thousands of clinical trial records across multiple active studies. That uncertainty is not an inconvenience; it is a source documentation crisis waiting to happen.
Sites carry a quiet assumption into every new study: the sponsor's systems will be up. That assumption is embedded in the site's own standard operating procedures, in the monitoring visit schedule, in the query resolution workflow, and in the IRT calls that govern IP dispensing. What almost no site SOP contains is a protocol for what to do when the sponsor side of that dependency fails. This matters operationally in a very precise way: ICH E6(R3) Section 5.5 requires that sponsors maintain validated, reliable electronic systems with adequate controls, including contingency plans for system failures. The burden sits with the sponsor. But the site is the one staring at a frozen screen with a subject in the waiting room.
The FDA's guidance on electronic systems in clinical investigations, published as "Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers," is explicit that regulated entities must consider data migration, data backup, data recovery, and contingency plans for systems used in clinical investigations. That framework applies to sponsors first and sites second. What it does not resolve is the handshake problem: who activates the contingency, how does that activation communicate to the site in real time, and what is the site authorized to do unilaterally before that communication arrives? In most protocol-defined workflows, sites cannot move to paper backup without explicit sponsor or CRO authorization. The authorization chain runs through the same IT environment that just went down.
Layered Vendor Dependency
Boston Scientific's use of Medidata's Rave EDC platform for clinical trial data collection and eConsent, documented in a Medidata case study, illustrates the layered vendor dependency that characterizes modern eClinical infrastructure. Even if a third-party EDC platform like Medidata Rave stays operational, access to it often depends on sponsor-controlled single sign-on, sponsor-managed user provisioning, and sponsor-hosted protocol configurations. If the sponsor's identity management systems are in the cyberattack's blast radius, sites can lose access to a platform that is technically online. The system is up; your login credentials are not.
Across the sites CliniBiz works with, the most common gap is not the absence of a paper backup form. Sites generally have those. The gap is the absence of a pre-authorized decision tree: at what point does the coordinator stop waiting for sponsor guidance and initiate the backup protocol unilaterally, and how does she document that decision in the source record without creating a deviation? An unplanned gap in EDC data entry is a finding. A paper backup initiated without authorization can also be a finding. Sites navigating a sponsor IT outage are threading between two deviation categories simultaneously, with no one picking up the phone on the sponsor side.
What the Outage Exposes About IRT and IP Dispensing
The EDC problem is recoverable if the outage is short. The IRT problem is not.
Interactive Response Technology systems govern investigational product dispensing. When a subject arrives for a dosing visit, the coordinator logs into IRT to confirm eligibility, assign the kit number, and document the dispense event. If the IRT system is inaccessible because it runs on sponsor-side infrastructure affected by the attack, the coordinator faces a binary choice: send the subject home or dispense without system confirmation. Neither option is acceptable. Sending an enrolled subject home for a dosing visit missed due to a sponsor-side IT failure is a protocol deviation. Dispensing IP without IRT confirmation is a pharmacy accountability gap and a potential GCP violation under 21 CFR Part 312 requirements for investigational drug accountability records. The window for making that call is narrow, typically measured in the minutes a subject is willing to wait in the waiting room before leaving.
Medtronic stated explicitly after its April 2026 incident that it had "not identified any impact to our products, patient safety, or connections to our customers" at the time of disclosure. That framing reflects the commercial product and patient device perspective, and it may be accurate for device connectivity. Clinical trial systems operate under a different clock. A 24-hour IRT outage during an active dosing week across a multi-site study is not a patient safety event in the acute sense. It is a cascade of missed visits, undocumented dispensing decisions, protocol deviations logged after the fact, and monitoring visit findings that accumulate for months. The damage shows up in data quality and enrollment velocity, not in an incident report.
What Operators Should Do Before the Next One
The action for site teams is concrete and overdue. Pull your current active protocols and identify every system in the visit workflow that is sponsored or partially sponsored infrastructure: EDC, IRT, central lab portals, ePRO platforms, eConsent platforms, and any sponsor-hosted investigator portal used for safety reporting or TMF access. For each one, your site SOP should document two things: the pre-authorized backup procedure (paper CRF, manual IP log, verbal PI authorization pathway) and the communication chain that activates it, including an emergency contact number that does not depend on the sponsor's own IT environment. If your monitoring plan does not already have that contact documented, request it at the next monitoring visit and get it in writing in your correspondence log.
For sponsor-side clinical operations teams, the minimum viable ask is a cyberattack-specific addendum to the Business Continuity Plan that covers clinical trial systems separately from commercial IT. The FDA's guidance on contingency planning for electronic systems gives you the regulatory hook to justify that separation to your IT leadership. Include a pre-authorized site communication template that sites can receive via SMS or personal email, not through the sponsor's own compromised email environment, authorizing manual backup protocols within the first hour of a confirmed outage. The Boston Scientific incident had no disclosed timeline for restoration. Any site operating an active study with a visit window open during that period needed that authorization before the outage happened, not after it was declared.
Cyberattacks against medtech sponsors are now frequent enough to belong in site qualification feasibility assessments alongside staffing capacity and equipment availability. The question "what is your contingency if the sponsor's eClinical infrastructure goes offline during a dosing visit?" should be part of every SIV agenda. Sites that can answer it are operationally ready. The ones that cannot are one incident away from a deviation cascade they did not plan for.